About
Technology
Issues
FAQ
Links
Official Page
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.